Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Resistant MOLM13 and MV4-11 cells have higher expression of MCL-1 or BCL-XL.
  • Fig. S2. Tedizolid treatment suppresses mitochondrial translation and increases sensitivity to pharmacologic inhibition of BCL-2 but not MCL-1 or BCL-XL.
  • Fig. S3. Doxycycline enhances sensitivity to venetoclax in CD34+ cells from primary AML samples.
  • Fig. S4. Venetoclax inhibits complex I activity.
  • Fig. S5. ISR activation is necessary and sufficient to sensitize AML cells to venetoclax.
  • Fig. S6. Combination treatment with tedizolid and venetoclax does not affect BCL-2 family members.
  • Fig. S7. ISRIB treatment prevents cell death by promoting glycolysis.
  • Fig. S8. Tedizolid treatment enhances the anti-leukemic activity of venetoclax in vivo.
  • Fig. S9. Combination treatment does not cause overt toxicities in PDX models.
  • Table S1. Engraftment potential of sorted CD34/CD38 fractions from primary AML sample 130578.
  • Table S2. Genetic characteristics of the primary AML samples and cell lines used in this study.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Gene sets enriched in tedizolid-treated cells.
  • Data file S2 (Microsoft Excel format). Gene sets enriched in venetoclax-treated cells.
  • Data file S3 (Microsoft Excel format). Gene sets enriched in cells treated with tedizolid and venetoclax.
  • Data file S4 (Microsoft Excel format). RNA expression of genes in the OXPHOS gene set normalized to values in DMSO control treated cells.
  • Data file S5 (Microsoft Excel format). Individual animal data from in vivo treatment studies.